Bradley Bliss
Medical · Wellston, MINPI 1114014180
Payments from drug & device makers
Across 101 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$418
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$375
- AstraZeneca$144
- Antares Pharma, Inc.$85
- Halozyme Inc$74
- Novo Nordisk$64
- plus $401 from 13 others
What the payments were for
- Food & beverage$1,561100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $418 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $375 |
| AstraZeneca | 8 | $144 |
| Antares Pharma, Inc. | 5 | $85 |
| Halozyme Inc | 4 | $74 |
| Novo Nordisk | 3 | $64 |
| GSK | 3 | $63 |
| Lilly USA, LLC | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| Bayer | 2 | $46 |
| Pfizer | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Astellas Pharma US Inc | 2 | $31 |
| Alkermes, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $5 |
How this compares
$1,561 in reported general payments places this provider in the 70th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 40 | $50,606 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $43,665 |
| TrulicityDulaglutide | 38 | $38,385 |
| EliquisApixaban | 36 | $30,963 |
| OzempicSemaglutide | 30 | $29,588 |
| JardianceEmpagliflozin | 19 | $26,402 |
| FarxigaDapagliflozin Propanediol | 22 | $21,568 |
| VraylarCariprazine Hcl | 13 | $19,315 |
| MounjaroTirzepatide | 14 | $14,492 |
| TradjentaLinagliptin | 19 | $10,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,738 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,027 |
| Novolog FlexpenInsulin Aspart | 13 | $2,702 |
| Ventolin HfaAlbuterol Sulfate | 41 | $2,508 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $52 | $52,87752 claims |
| GSKTrelegy Ellipta | $63 | $43,66564 claims |
| PfizerEliquis | $39 | $30,96336 claims |
| Novo NordiskOzempic | $64 | $29,58830 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $144 | $29,30634 claims |
| AbbVieVraylar | $418 | $19,31513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 755 medical providers in Michigan.
Other medical in Wellston
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.